ASTRANA HEALTH INC (ASTH) Stock Fundamental Analysis
USA - NASDAQ:ASTH - US03763A2078 - Common Stock
33.24 USD
+0.14 (+0.42%)
33.24 USD
0 (0%)
ASTH gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 100 industry peers in the Health Care Providers & Services industry. The financial health of ASTH is average, but there are quite some concerns on its profitability. ASTH is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year ASTH was profitable.
In the past year ASTH had a positive cash flow from operations.
In the past 5 years ASTH has always been profitable.
In the past 5 years ASTH always reported a positive cash flow from operatings.
1.2 Ratios
ASTH has a Return On Assets (1.75%) which is comparable to the rest of the industry.
ASTH's Return On Equity of 3.30% is in line compared to the rest of the industry. ASTH outperforms 58.00% of its industry peers.
Looking at the Return On Invested Capital, with a value of 4.50%, ASTH is in line with its industry, outperforming 51.00% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for ASTH is below the industry average of 9.42%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | 3.3% | ||
| ROIC | 4.5% |
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
1.3 Margins
With a Profit Margin value of 1.04%, ASTH perfoms like the industry average, outperforming 57.00% of the companies in the same industry.
In the last couple of years the Profit Margin of ASTH has declined.
Looking at the Operating Margin, with a value of 2.90%, ASTH is in line with its industry, outperforming 54.00% of the companies in the same industry.
ASTH's Operating Margin has declined in the last couple of years.
ASTH's Gross Margin of 11.30% is on the low side compared to the rest of the industry. ASTH is outperformed by 73.00% of its industry peers.
In the last couple of years the Gross Margin of ASTH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.9% | ||
| PM (TTM) | 1.04% | ||
| GM | 11.3% |
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ASTH is destroying value.
The number of shares outstanding for ASTH has been increased compared to 1 year ago.
The debt/assets ratio for ASTH is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.82 indicates that ASTH is not in any danger for bankruptcy at the moment.
ASTH has a better Altman-Z score (3.82) than 73.00% of its industry peers.
ASTH has a debt to FCF ratio of 3.41. This is a good value and a sign of high solvency as ASTH would need 3.41 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 3.41, ASTH is doing good in the industry, outperforming 75.00% of the companies in the same industry.
A Debt/Equity ratio of 0.52 indicates that ASTH is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.52, ASTH is in the better half of the industry, outperforming 61.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 3.82 |
ROIC/WACC0.5
WACC9.01%
2.3 Liquidity
A Current Ratio of 1.59 indicates that ASTH should not have too much problems paying its short term obligations.
ASTH has a Current ratio (1.59) which is in line with its industry peers.
ASTH has a Quick Ratio of 1.59. This is a normal value and indicates that ASTH is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ASTH (1.59) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.59 |
3. Growth
3.1 Past
ASTH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -64.58%.
The Earnings Per Share has been growing by 19.19% on average over the past years. This is quite good.
The Revenue has grown by 51.97% in the past year. This is a very strong growth!
The Revenue has been growing by 38.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-64.58%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-52.5%
Revenue 1Y (TTM)51.97%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%34.66%
3.2 Future
ASTH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.87% yearly.
The Revenue is expected to grow by 20.51% on average over the next years. This is a very strong growth
EPS Next Y37.27%
EPS Next 2Y52.57%
EPS Next 3Y45.45%
EPS Next 5Y31.87%
Revenue Next Year61.55%
Revenue Next 2Y43.26%
Revenue Next 3Y31.12%
Revenue Next 5Y20.51%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 65.18, the valuation of ASTH can be described as expensive.
ASTH's Price/Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Earnings ratio of 26.13, ASTH is valued quite expensively.
ASTH is valuated correctly with a Price/Forward Earnings ratio of 16.04.
Based on the Price/Forward Earnings ratio, ASTH is valued a bit cheaper than the industry average as 74.00% of the companies are valued more expensively.
ASTH's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 65.18 | ||
| Fwd PE | 16.04 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ASTH is on the same level as its industry peers.
Based on the Price/Free Cash Flow ratio, ASTH is valued a bit cheaper than 80.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.69 | ||
| EV/EBITDA | 17.35 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as ASTH's earnings are expected to grow with 45.45% in the coming years.
PEG (NY)1.75
PEG (5Y)3.4
EPS Next 2Y52.57%
EPS Next 3Y45.45%
5. Dividend
5.1 Amount
ASTH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
33.24
+0.14 (+0.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners53.14%
Inst Owner ChangeN/A
Ins Owners9.76%
Ins Owner Change0.2%
Market Cap1.66B
Revenue(TTM)2.42B
Net Income(TTM)25.26M
Analysts85
Price Target45.9 (38.09%)
Short Float %4.3%
Short Ratio5.12
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.09
Dividend Growth(5Y)N/A
DP33.15%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-46.54%
Min EPS beat(2)-48.7%
Max EPS beat(2)-44.39%
EPS beat(4)1
Avg EPS beat(4)-79.13%
Min EPS beat(4)-225.16%
Max EPS beat(4)1.74%
EPS beat(8)5
Avg EPS beat(8)-25.47%
EPS beat(12)8
Avg EPS beat(12)-7.32%
EPS beat(16)11
Avg EPS beat(16)2.37%
Revenue beat(2)1
Avg Revenue beat(2)-1.49%
Min Revenue beat(2)-3.56%
Max Revenue beat(2)0.57%
Revenue beat(4)3
Avg Revenue beat(4)1.04%
Min Revenue beat(4)-3.56%
Max Revenue beat(4)5.66%
Revenue beat(8)5
Avg Revenue beat(8)0.88%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.88%
EPS NY rev (1m)0%
EPS NY rev (3m)0.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 65.18 | ||
| Fwd PE | 16.04 | ||
| P/S | 0.69 | ||
| P/FCF | 13.69 | ||
| P/OCF | 12.71 | ||
| P/B | 2.17 | ||
| P/tB | 6.84 | ||
| EV/EBITDA | 17.35 |
EPS(TTM)0.51
EY1.53%
EPS(NY)2.07
Fwd EY6.23%
FCF(TTM)2.43
FCFY7.31%
OCF(TTM)2.61
OCFY7.87%
SpS48.45
BVpS15.33
TBVpS4.86
PEG (NY)1.75
PEG (5Y)3.4
Graham Number13.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | 3.3% | ||
| ROCE | 7.13% | ||
| ROIC | 4.5% | ||
| ROICexc | 6.9% | ||
| ROICexgc | 37.52% | ||
| OM | 2.9% | ||
| PM (TTM) | 1.04% | ||
| GM | 11.3% | ||
| FCFM | 5.01% |
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ROICexc(3y)11.13%
ROICexc(5y)11.73%
ROICexgc(3y)50.18%
ROICexgc(5y)49.73%
ROCE(3y)11.21%
ROCE(5y)11.68%
ROICexgc growth 3Y-13.47%
ROICexgc growth 5YN/A
ROICexc growth 3Y-16.27%
ROICexc growth 5YN/A
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
F-Score5
Asset Turnover1.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 4.04 | ||
| Cap/Depr | 31.97% | ||
| Cap/Sales | 0.39% | ||
| Interest Coverage | 8.53 | ||
| Cash Conversion | 131.6% | ||
| Profit Quality | 480.02% | ||
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.59 | ||
| Altman-Z | 3.82 |
F-Score5
WACC9.01%
ROIC/WACC0.5
Cap/Depr(3y)106.76%
Cap/Depr(5y)87.27%
Cap/Sales(3y)1.49%
Cap/Sales(5y)1.42%
Profit Quality(3y)99.59%
Profit Quality(5y)98.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-64.58%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-52.5%
EPS Next Y37.27%
EPS Next 2Y52.57%
EPS Next 3Y45.45%
EPS Next 5Y31.87%
Revenue 1Y (TTM)51.97%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%34.66%
Revenue Next Year61.55%
Revenue Next 2Y43.26%
Revenue Next 3Y31.12%
Revenue Next 5Y20.51%
EBIT growth 1Y-26.57%
EBIT growth 3Y-3.09%
EBIT growth 5YN/A
EBIT Next Year116.25%
EBIT Next 3Y48.23%
EBIT Next 5Y33.37%
FCF growth 1Y11.26%
FCF growth 3Y-4.75%
FCF growth 5YN/A
OCF growth 1Y-23.49%
OCF growth 3Y-9.46%
OCF growth 5YN/A
ASTRANA HEALTH INC / ASTH FAQ
Can you provide the ChartMill fundamental rating for ASTRANA HEALTH INC?
ChartMill assigns a fundamental rating of 5 / 10 to ASTH.
What is the valuation status for ASTH stock?
ChartMill assigns a valuation rating of 4 / 10 to ASTRANA HEALTH INC (ASTH). This can be considered as Fairly Valued.
How profitable is ASTRANA HEALTH INC (ASTH) stock?
ASTRANA HEALTH INC (ASTH) has a profitability rating of 3 / 10.
What is the financial health of ASTRANA HEALTH INC (ASTH) stock?
The financial health rating of ASTRANA HEALTH INC (ASTH) is 5 / 10.
Is the dividend of ASTRANA HEALTH INC sustainable?
The dividend rating of ASTRANA HEALTH INC (ASTH) is 0 / 10 and the dividend payout ratio is 33.15%.